CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 137 enrolled
Drug / intervention
VIGAMOXdrug
Likely dose
Moxifloxacin (VIGAMOX) 0.5% ophthalmic solution, 1 drop in both eyes three times daily for 7 daysAI-extracted
Key inclusion· 4
  • ✓Age 1 to 13 years
  • ✓Clinical diagnosis of bacterial conjunctivitis in one or both eyes
  • ✓Symptom duration less than 3 days
  • ✓Healthy control participants
Key exclusion· 1
  • ✕Symptom duration greater than 2 days at enrollment

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00312338
NCT00312338Phase 4Completed
CompareCT.gov

Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora

Alcon Research·interventional·Posted Apr 10, 2006·Updated Nov 2, 2012

In Brief

A Phase 4 clinical trial evaluating VIGAMOX for Bacterial Conjunctivitis. Completed, enrolled 137 participants across 1 site.

Detailed Summary

Topical Treatment of Bacterial Conjunctivitis and its Effect on Microbial Flora

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Conjunctivitis
CountriesUnited States
CollaboratorsTufts University

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 10, 2006
Enrollment StartJun 1, 2006
Primary CompletionJun 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 20.2 years ago

Interventions

VIGAMOXdrug

1 drop of VIGAMOX® ophthalmic solution 0.5% in both eyes TID for 7 days